Raimondo, Stefania
Cristaldi, Marta
Fontana, Simona
Saieva, Laura
Monteleone, Francesca
Calabrese, Giovanna
Giavaresi, Gianluca
Parenti, Rosalba
Alessandro, Riccardo
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (18783)
Article History
Received: 12 January 2018
Accepted: 6 April 2018
First Online: 13 April 2018
Ethics approval
: The study was conducted in compliance with Italian and European laws concerning animal experiments. The research protocol “Sviluppo e caratterizzazione di modelli animali di xenotrapianto di tumori solidi, cellule tumorali e staminali tumorali da neoplasie umane” was authorized by Italian Ministry of Health (2014/01/13) according to Legislative Decree 116/92 and was performed according to Legislative Decree 26/2014.
: The authors declare that there are no competing interests that could be perceived as prejudicing the impartiality of the research reported. A patent on the use ofCitrus limonL.-derived nanovesicles as antineoplastic agents has been granted (n°102015902344749). A patent on the use of oligonucleotides complementary to DDHD1 and their use in tumor prevention and treatment has been filed (n°102017000060905, June 5th 2017).
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.